IMUNON Reports Second Quarter 2023 Financial Results and Provides Business Update
Advances Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet Conference Call...